Recombinant Microorganisms for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for terminal diseases, such as cancer, face challenges with targeted therapies having limited responders and adverse effects due to non-specific drug delivery, and existing methods like immunotherapy and gene therapy suffer from scalability and reproducibility issues.
Innovation Solution
Development of recombinant microorganisms engineered to produce podophyllotoxin or its derivatives, like etoposide, which are capable of targeting cancer cells by secreting the drug at the tumor site, reducing systemic drug levels and minimizing adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat terminal diseases, then disease treatment is achieved, but adverse effects are amplified due to prolonged drug intake and difficulty in managing dosages
Solution Approach 1:
The patent uses engineered microorganisms as intermediaries to deliver therapeutic compounds locally at the disease site. These microorganisms act as living carriers that produce and deliver drugs like podophyllotoxin and etoposide directly to tumors, bypassing the need for systemic chemotherapy and its associated adverse effects
Solution Approach 2:
The engineered microorganisms possess the ability to self-produce therapeutic compounds through integrated biosynthetic pathways. The microorganisms express multiple enzymes (PAL, C4H, 4CL, HCT, C3H, CCoAOMT, DIRPLR, SDH, CYP719, OMT, CYP71, 2-ODD) to synthesize podophyllotoxin and its derivatives internally, eliminating the need for external drug administration
2Reliability
If immunotherapy is used to treat terminal diseases, then some patients respond positively, but the response rate is limited to only one in five patients
Solution Approach 1:
The patent employs regulatory circuits that sense and respond to specific microenvironmental parameters (pH, redox potential, enzymes) characteristic of tumor sites. This allows the therapeutic compounds to be produced only when the microorganisms detect tumor-specific conditions, enhancing efficacy in responsive patients while minimizing effects in non-responders
3Object-affected harmful factors
If targeted drug delivery systems are used to reduce adverse effects, then dosages can be precisely delivered to target sites, but scalability and reproducibility remain challenging
Solution Approach 1:
The engineered microorganisms contain complete biosynthetic pathways for producing podophyllotoxin and etoposide, along with regulatory circuits that automatically activate production under tumor-specific conditions. This self-sufficient design eliminates the need for complex external delivery infrastructure, enabling scalable manufacturing through standard microbial culture techniques
Solution Approach 2:
The patent designs a universal platform where a single engineered microorganism strain can produce multiple therapeutic compounds (podophyllotoxin, etoposide, and their derivatives) through a shared set of biosynthetic enzymes and regulatory mechanisms. This multi-functional design simplifies manufacturing and enhances reproducibility across different therapeutic applications
Data Source
AI summary
The present disclosure discloses a recombinant microbe producing podophyllotoxin, or its derivatives, comprising genes encoding phenyl alanine ammonia-lyase (PAL), cinnamate-4-hydroxylate (C4H), 4-coumaroyl CoA-ligase (4CL), hydroxycinnamoyl-CoA quinate hydroxycinnamoyltransferase (HCT), p-coumaroyl quinate 3′-hydroxylase (C3H), caffeoyl CoA O-methyltransferase (CCoAOMT), bifunctional pinoresinol-lariciresinol reductase (DIRPLR), secoisolariciresinol dehydrogenase (SDH), cytochrome P450 oxidoreductase CYP719, O-methyltransferase (OMT), cytochrome P450 oxidoreductase CYP71, and 2-oxoglutarate/Fe(II)-dependent dioxygenase (2-ODD). Also disclosed herein is a method for producing podophyllotoxin or its derivatives. Moreover, a method of treating cancer is also disclosed.